BSE · 543594
Dipna Pharmachem Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹125 Cr with net profit ₹1 Cr — a 0.78% net margin, versus 0.66% the period before.
Shareholding
As of 2026-03-31
- Promoter9.13%
- Public90.87%
1,717 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 6.41× from low to high.
Risk flags
Derived from disclosed data
- 52-week range spans 6.41× (₹3.9 to ₹25) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #89 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Dipna Pharmachem Limited(this company) | ₹11 Cr | 4.22 | 0.18 | 4.22% | 2.07% |
AI analysis
AI-generated · google/gemini-2.5-flashDipna Pharmachem Limited is listed with a market capitalization of Rs 14 Cr. The company has a PE ratio of 5.3 and an EPS of 1. The book value per share is Rs 23.7, with a return on equity (ROE) of 422.43% and return on capital employed (ROCE) of 6.63%.
Positives
- +The profit margin for the company is 207.03%.
- +Return on Equity (ROE) is 422.43%.
- +Debt-to-equity ratio at 0.48 indicates moderate leverage.
Negatives
- −Promoter holding decreased from 66.56% in March 2023 to 9.13% in March 2026.
- −Revenue decreased from Rs 164.34 Cr in March 2024 to Rs 124.93 Cr in March 2025.
- −Net profit decreased from Rs 1.09 Cr in March 2024 to Rs 0.97 Cr in March 2025.
- −No quarterly results have been disclosed since March 2026.
Financial Performance
In the fiscal year ending March 2025, Dipna Pharmachem Limited reported revenue of Rs 124.93 Cr. This was a decrease from the Rs 164.34 Cr reported in March 2024. Net profit for March 2025 was Rs 0.97 Cr, down from Rs 1.09 Cr in March 2024. The company has not provided quarterly results since March 2026.
Profitability & Returns
Dipna Pharmachem Limited reported a profit margin of 207.03%. The return on equity (ROE) stands at 422.43%, while the return on capital employed (ROCE) is 6.63%. The company's EPS was 1 at the time of data collection.
Balance Sheet
The company's debt-to-equity ratio is 0.48. As of the latest available data, the book value per share is Rs 23.7. No further details on the balance sheet, such as assets or liabilities, were provided.
Ownership & Pledges
As of March 31, 2026, promoter holding in Dipna Pharmachem Limited was 9.13%, with public shareholders holding 90.87%. There were no shares pledged by the promoters. The number of shareholders was 1717.
Regulatory & Surveillance
No information regarding regulatory actions or surveillance measures against Dipna Pharmachem Limited was provided in the available data. The company has not been subject to any reported surveillance from regulatory bodies.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.